Conestat Alfa (a Recombinant Human C1 Esterase Inhibitor) for the Prevention of Acute Kidney Injury After Non-ST Elevation Myocardial Infarction: a Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2, Dose-finding Study

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 08 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Conestat alfa (Primary)
Indications Acute kidney injury
Focus Registrational; Therapeutic Use
Sponsors Pharming Group NV

Most Recent Events

01 Apr 2024 Status changed from recruiting to discontinued due to low enrollment rate and for new strategic considerations.
04 Aug 2021 According to a Pharming Group NV media release, first patient has been enrolled at the University Hospital Basel, Switzerland.
27 Apr 2021 Planned number of patients changed to 220.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight